1 completed, 1 not yet recruiting, 1 no longer available. 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Not yet recruiting 1 |
| Phase 4 | 1 | Completed 1 |
Follow Triclabendazole: new trials by email Literature Review of Triclabendazole trials Research Report on Triclabendazole
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole in Chronic Fascioliasis Oxfendazole, Triclabendazole - Fascioliasis | Phase 2 | Not yet recruiting | Universidad Peruana Cayetano Heredia | 336 | 2026-08-15 | 2026-06-03 |
| Study of Safety, Tolerability and Clinical Outcomes of Egaten in Fascioliasis Patients (6 Years of Age or Older). Egaten (Triclabendazole) 250 mg tablets - Fascioliasis | Phase 4 | Completed | Novartis Pharmaceuticals | 301 | 2022-02-11 | 2026-10-06 |
| Compassionate Use of Triclabendazole for the Treatment of Parasites (Prior to FDA Approval; Expanded Access Program) Triclabendazole - Parasitic Disease | No longer available | University of Colorado, Denver | 2021-05-04 |
Fascioliasis (2) · Parasitic Diseases (1)
Novartis Pharmaceuticals (1) · Universidad Peruana Cayetano Heredia (1) · University of Colorado, Denver (1)
Colombia (1) · Egypt (1) · Peru (1) · Turkey (Türkiye) (1) · Vietnam (1)
Hector H Garcia, MD PhD (1) · Lourdes Rodriguez, MD (1) · Marilyn Levi, MD (1) · Miguel M Cabada, MD MSc (1)
U01AI155323 (1)